Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant

類似資料

• A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia
  著者:: Zheng, Hong, 等
  出版事項: (2020)
• Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
  著者:: Zhao, Chenchen, 等
  出版事項: (2019)
• VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
  著者:: Wang, Liru, 等
  出版事項: (2018)
• Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients
  著者:: Jia, Bei, 等
  出版事項: (2018)
• Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
  著者:: Wirk, Baldeep, 等
  出版事項: (2013)